Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 13-24 of 77 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn how to use the finder by watching this video.
Showing 13-24 of 77 studies
-
Restore CFTR ProteinClosed to Enrollment
RESTORE-CF: Phase 1/2 study of MRT5005 drug in adults with cystic fibrosis (Parts A, B and B Expansion) , protocol number Translate Bio MRT5005-101This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of different doses of the nebulized drug MRT5005 in adults with CF.
-
Age:
18 Years and Older
-
Mutation(s):
Mutation Requirement
-
FEV1% Predicted:
50 to 90%
-
Number of Visits:
21
-
Length of Participation:
1 years
-
-
Restore CFTR ProteinClosed to Enrollment
Phase 3 study of long-term ivacaftor in babies who have a CFTR gating mutation , protocol number Vertex VX-770-126This open-label study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of long-term ivacaftor in babies who have a CFTR gating mutation.
-
Age:
Less than 25 Months
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
18
-
Length of Participation:
128 weeks
-
-
Restore CFTR ProteinClosed to Enrollment
Phase 1/2 study of PTI-801 drug in healthy adults and then in adults with cystic fibrosis , protocol number Proteostasis PTI-801-01This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of the drug PTI-801.
-
Age:
18 Years and Older
-
Mutation(s):
Two Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
8
-
Length of Participation:
30 days
-
-
Restore CFTR ProteinClosed to Enrollment
Phase 3 study of ivacaftor in babies who have a CFTR gating mutation , protocol number Vertex VX15-770-124This two-part, open-label study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of ivacaftor, as well as how the body processes the drug, in babies who have a CFTR gating mutation.
-
Age:
Less than 13 Months
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
8
-
Length of Participation:
24 weeks
-
-
Restore CFTR ProteinClosed to Enrollment
SNO7: Phase 2 study of N91115 in adults with CF who are currently taking ivacaftor , protocol number Nivalis N91115-2CF-06This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the oral drug N91115 and will use a placebo control.
-
Age:
18 Years and Older
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
8
-
Length of Participation:
12 weeks
-
-
Anti-InfectiveClosed to Enrollment
Study of Lefamulin in Adults with CF , protocol number Nabriva NAB-BC-3781-1014This study will look at the safety and how the body processes lefamulin, a drug intended to treat infections in the lung. This study is for adults with CF.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
6
-
Length of Participation:
13 days
-
-
ObservationalClosed to Enrollment
HERO-2 , protocol number HERO2-OB-2This study will collect everyday observations that individuals with CF, who are taking the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor (Trikafta®), make in their daily lives over 12 months. Participants will use the Folia app to track their routine treatments, medication usage, and symptoms, and will answer validated patient-reported outcome questionnaires. Participants who are participating in the CF Patient Registry will have their Registry data linked to their Folia tracking data to assess the relationship between any medication changes and changes in lung function. This study will not provide or make any treatment recommendations, and there are no required study visits.
-
Age:
12 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
0
-
Length of Participation:
12 months
-
-
ObservationalClosed to Enrollment
Study to evaluate the effects of the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor in children (PROMISE Pediatric Cohort) , protocol number PROMISE-OB-18 - Pediatric CohortThis observational study will measure the effects of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor, in children with CF. These drugs are intended to help CFTR protein function closer to normal. This study will look at how treatment with the triple-combination therapy affects children with CF across many different aspects of the disease.
-
Age:
6 Years to 11 Years
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
8
-
Length of Participation:
4 years
-
-
ObservationalClosed to Enrollment
Study to evaluate the effects of the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor (PROMISE) , protocol number PROMISE-OB-18PROMISE is a postapproval, real-world, observational study to understand the effects of elexacaftor/tezacaftor/ivacaftor (ETI) in clinical use in the United States.
-
Age:
12 Years and Older
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
8
-
Length of Participation:
4 years
-
-
ObservationalClosed to Enrollment
An Ocular Safety Study of Kalyedeco-Treated Children 11 Years of Age or Younger with CF , protocol number Vertex VX-770-115This trial is designed to evaluate the risk of cataracts (lens opacities) and describe the best corrected distance vision (with glasses/contacts for those who wear them) of children with Cystic Fibrosis who are 11 years of age or younger at the time of ivacaftor (Kalydeco) treatment initiation and are receiving or planning to receive commercially-available ivacaftor (Kalydeco) in the US.
-
Age:
6 Years to 11 Years
-
Mutation(s):
One Copy F508del or No Copies F508del
-
FEV1% Predicted:
No FEV1 Limit
-
Number of Visits:
5
-
Length of Participation:
2 years
-
-
Restore CFTR ProteinCompleted with Results
Study of VX-445 Triple Combination in Teens and Adults With Cystic Fibrosis (CF) Who Have One Copy of F508del and One Copy of a Gating or Residual Function Mutation , protocol number Vertex VX18-445-104This study evaluated the safety and effectiveness of VX-445 (elexacaftor), tezacaftor, and ivacaftor in combination called TRIKAFTA®. This study was for people with CF 12 years and older with one copy of the F508del mutation and one copy of a gating or residual function mutation.
-
Age:
12 Years and Older
-
Mutation(s):
One Copy F508del
-
FEV1% Predicted:
40 to 90%
-
Number of Visits:
8
-
Length of Participation:
20 weeks
-
-
Restore CFTR ProteinCompleted with Results
Study of VX-445 triple combination in children 6-11 years old with cystic fibrosis , protocol number Vertex VX18-445-106This study evaluated the safety and effectiveness of the triple combination modulator therapy, elexacaftor/tezacaftor/ivacaftor (Trikafta®) in children ages 6-11 years with CF, who have either two copies of the F508del mutation or one copy of the F508del mutation and one minimal function mutation.
-
Age:
6 Years to 11 Years
-
Mutation(s):
Two Copies F508del or One Copy F508del
-
FEV1% Predicted:
40% or greater
-
Number of Visits:
9
-
Length of Participation:
32 weeks
-
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More